eXoZymes, Inc. (EXOZ)
Nasdaq · Healthcare · Biotechnology
$5.52−4.33%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $51.4M
- 52-week range
- $4.35 – $18.40
- 52-week change
- −57.26%
- EPS (trailing)
- −$1.24
Fiscal year to Dec 2025
- Net income
- −$9.2M
- Diluted EPS
- −$1.09
- Free cash flow
- −$6.7M
From the company’s annual report on SEC EDGAR.
About eXoZymes, Inc.
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.
Headquarters: Monrovia, United States · 32 employees · exozymes.com